RxDoctor Payments Data

Cathy Lucas

Family · Ottawa, OHNPI 1124695606

Payments from drug & device makers

$6,417in general payments, 2019–2025

Across 377 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • AbbVie$925
  • Lucid Diagnostics Inc.$724
  • Johnson & Johnson$679
  • Ardelyx, Inc.$273
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,35499%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,417 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$68,567
Medicare patients
436
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$127,886
XifaxanRifaximin28$85,983
LinzessLinaclotide59$58,208
Dexlansoprazole DrDexlansoprazole34$12,926
Mesalamine16$10,789
Pantoprazole Sodium334$6,910
Omeprazole376$5,635
Sucralfate91$5,193
Esomeprazole Magnesium66$4,204
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates61$3,631
CholestyramineCholestyramine (With Sugar)38$3,282
Lubiprostone29$2,830
Dicyclomine Hcl80$1,881
Famotidine129$1,599
Lansoprazole24$1,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,101$85,98328 claims
AbbVieLinzess$925$58,20859 claims
SandozLansoprazole$16$1,22724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Ottawa

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →